• Secondly as pointed out by Sulentic and Kaminski in

  2024-08-06

  

  Secondly, as pointed out by Sulentic and Kaminski in their recent paper [90], most of the AhR literature to date has focused on mouse AhR. Although both mouse and human AhR are interchangeable in many in vitro systems, the in vivo ligand binding affinity is drastically different between the two AhRs

• br Conflict of Interest br Transparency Document br Introduc

  2024-08-06

  

  Conflict of Interest Transparency Document Introduction Mitoxantrone (MXT) is an androstenedione chemotherapeutic agent that is used to treat acute nonlymphocytic leukemia, acute lymphoblastic leukemia, prostate cancer, metastatic breast cancer, and non-Hodgkin’s lymphoma [13], [14]. It is

• br ACK inhibitors Since ACK

  2024-08-06

  

  ACK1 inhibitors Since ACK1 activation is correlated with poor prognosis in various cancers, strong efforts are being directed by multiple groups towards developing highly potent and specific small molecule inhibitors targeting the ACK1 kinase. At least eight small molecule kinase inhibitors have

• Young disease transitioning B Sle mice show partial loss

  2024-08-05

  

  Young disease-transitioning B6·Sle1 mice show partial loss of leukocyte Axl versus B6 controls (data not shown). Further, BMDM from diseased B6·Sle1.Yaa mice do not express detectable levels of ADAM10 and TACE (ADAM17) but do express basal levels of Axl similar to wild type B6-derived BMDM (Suppleme

• protease inhibitor A variety of quinazoline or fused pyrimid

  2024-08-05

  

  A variety of quinazoline or fused pyrimidine-substituted diaminotriazoles showed sub-100nM inhibition of Axl (). Diaminotriazoles similarly substituted with quinolines, isoquinolines and benzothiazoles also showed potent Axl activity (data not shown), but generally exhibited potent cytotoxicity and

• br Materials and methods br

  2024-08-05

  

  Materials and methods Results Discussion Numerous studies showed that Na+-K+-ATPase activity and membrane Doxorubicin HCl were decreased in cardiac tissue subjected to IR (Belliard et al., 2013; Lee et al., 2013). In return, treatment that alleviated the progress of IR-related myocardial i

• KH CB19 br Experimental section br Competing

  2024-08-05

  

  Experimental section Competing interests Author's contributions Acknowledgement This research is partially supported by a seed fund for the Center for Drug Discovery and Translational Research (LS) and a research grant by Fujifilm (VPS and LS). The Sponsors played no roles in study desig

• Immunohistochemistry in tissue samples showed the expression

  2024-08-05

  

  Immunohistochemistry in tissue samples showed the expression of several nuclear receptor co-activators, including NCOA1, NCOA2, NCOA3, CREBBP, and EP300, in 85–100% of Veliparib tumors even some of which lacked AR expression (Boorjian et al., 2009). Knockdown of each co-activator also resulted in s

• Most of the identified aldose reductase inhibitors

  2024-08-05

  

  Most of the identified aldose reductase inhibitors possess undesirable effects like poor pharmacokinetic properties, hypersensitivity and Steven-Johnson Syndrome [1]. However, the main side effect is the lack of selectivity relative to aldehyde reductase (ALR1, EC 1.1.1.2). ALR1 plays the important

• SB 366791 Bioactive peptides contain amino acids with possib

  2024-08-03

  

  Bioactive peptides contain 2–20 amino acids with possible bioactivities including antihypertensive, antioxidant, antimicrobial, anticancer, and opioid activity [9], [10], [11]. There has been a great interest in antihypertensive peptides for their efficiency in lowering blood pressure. The antihyper

• Thus one possible target for CRPC

  2024-08-03

  

  Thus one possible target for CRPC treatment is the enzyme 17,20-lyase, which plays a crucial role in androgen biosynthesis. This is because inhibition of 17,20-lyase would be expected to decrease serum androgen levels secreted not only by the testes but also by the adrenal glands.7, 8, 9 In recent

• Consistent with a damaging role for increased LOX

  2024-08-03

  

  Consistent with a damaging role for increased 12/15-LOX activity in stroke, systemic administration of the 12/15-LOX inhibitor, LB1, 2 h after permanent focal cerebral ischemia significantly reduced infarct size 24 h after the ischemia, and the treatment group demonstrated improved behavioral and he

• br Drugs with documented pro apoptotic effects on

  2024-08-03

  

  Drugs with documented pro-apoptotic effects on platelets More than 200 drugs are reported to cause thrombocytopenia [5,42]. The concept of platelet apoptosis is relatively new and was only recently evaluated in the context of drug-induced thrombocytopenia [43]. Table 2 lists the drugs presently

• According to the present observations the

  2024-08-03

  

  According to the present observations, the Ampkα1 isoform promotes AP-1 transcriptional activity and thereby fosters 2 nbdg of AP-1 target genes in cardiomyocytes via activation of Pkcζ. The transcription factor AP-1 plays a decisive role during cardiac remodeling [24], [25], [26], [37]. AP-1 modul

• br Conclusions In summary KLA isolated from K

  2024-08-03

  

  Conclusions In summary, KLA isolated from K. senegalensis exerted the anti-inflammatory activity via inhibiting the activation of NF-κB, AP-1, AKT and upregulating p38 MAPK/Nrf2/HO-1 signaling in LPS-stimulated RAW 264.7 and BV-2 Tenovin-1 (Fig. 9). These properties provide a potential mechanism

15438 records 73/1030 page Previous Next First page 上5页 7172737475 下5页 Last page